Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder
Jean Endicott,1 Henrik Svedsäter,2 Julie C Locklear21Department of Psychiatry, Columbia University, New York, NY; 2AstraZeneca Pharmaceuticals, Wilmington, DE, USABackground: We evaluated the effects of once-daily extended-release quetiapine fumarate (quetiapine XR) on patient-reported...
Guardado en:
Autores principales: | Endicott J, Svedsäter H, Locklear JC |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4c48c3d25c844b1dbba96802ad7b0b38 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders
por: El-Khalili N
Publicado: (2012) -
The management of schizophrenia: focus on extended-release quetiapine fumarate
por: Peuskens J
Publicado: (2011) -
Role of extended release quetiapine in the management of bipolar disorders
por: Rayan K Al Jurdi, et al.
Publicado: (2010) -
Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
por: Pefura Yone EW, et al.
Publicado: (2012) -
Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
por: Mann KV, et al.
Publicado: (2014)